Loading

lorems ipsum dolor est

The standard Lorem Ipsum passage, used since the 1500s “Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse […]

Results Presented at the 2017 AAD

Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis. Menlo Therapeutics Inc. (Menlo Park, CA) announced today that the phase 2 trial (TCP-102) evaluating serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis successfully met its primary efficacy endpoint and key secondary endpoints, […]

Enrollment Starts for Two Studies

Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK‐1) receptor antagonist, serlopitant, for the treatment of pruritus (itch) associated with atopic dermatitis and for the treatment […]

Leadership And Directors

Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus Menlo Therapeutics Inc., a clinical stage pharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant, VPD‐737) for the treatment of pruritus (itch). Over the past 16 months, Menlo Therapeutics established direct operations to advance serlopitant […]

Exclusive License Agreement

Menlo Therapeutics Inc., (Menlo Park, CA) announced today that it has entered into an exclusive license agreement with Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) for the development and commercialization of serlopitant in Japan. Serlopitant is a first–in-class, once-daily oral NK-1 receptor antagonist candidate for the treatment of pruritus. Serlopitant has demonstrated antipruritic […]